eClinical Tech News

aTyr Pharma released interim Phase 2 data for efzofitimod, a potential treatment for systemic sclerosis-related interstitial lung disease (SSc-ILD)....

Rectify Pharmaceuticals presented data on RTY-822, a positive functional modulator (PFM) targeting the ABCC6 membrane transporter, at the 2025...

Actuate Therapeutics’ Phase 2 trial of elraglusib combined with gemcitabine/nab-paclitaxel (GnP) achieved its primary endpoint, demonstrating a statistically significant...

ImPact Biotech announced interim Phase 3 trial results for Padeliporfin VTP, a treatment for low-grade upper tract urothelial cancer...

HUTCHMED announced positive interim results from its SACHI Phase III study, showing that the combination of savolitinib and osimertinib...

Arvinas and Pfizer announced positive Phase 3 VERITAC-2 trial results for vepdegestrant, a novel oral PROTAC ER degrader for...

Teva Pharmaceuticals presented data at the 2025 Psych Congress Elevate Annual Meeting showcasing positive real-world results for UZEDY (risperidone)...

NurExone Biologic Inc. announced that Professor Nahshon Knoller will present at the American Spinal Injury Association (ASIA) annual meeting....

PolyPid Ltd., a late-stage biopharmaceutical company, is preparing to release topline results from its phase 3 SHIELD II trial...

Regeneron and Sanofi announced Phase 3 trial results for itepekimab, a potential COPD treatment for former smokers. AERIFY-1 met...